PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Phase 2
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00037219
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
Phase 2
Completed
- Conditions
- Aspergillosis
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00037206
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Phase 2
Terminated
- Conditions
- Neoplasm MetastasisColorectal Neoplasms
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT00037180
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
Phase 3
Completed
- Conditions
- Bacterial InfectionsGram-Positive Bacterial InfectionsBacteremia
- First Posted Date
- 2002-05-15
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 739
- Registration Number
- NCT00037050
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
Phase 3
Completed
- Conditions
- Parkinson Disease
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2006-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00036218
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Phase 3
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9779
- Registration Number
- NCT00036270
- Locations
- 🇺🇸
Pfizer Investigational Site, Vancouver, Washington, United States
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00036140
- Locations
- 🇺🇸
Research Center, Marshfield, Wisconsin, United States
Chemoprevention of Oral Premalignant Lesions
Phase 2
Completed
- Conditions
- Precancerous Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00036283
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
Phase 3
Terminated
- Conditions
- Parkinson Disease
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2007-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 984
- Registration Number
- NCT00036205
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
Phase 3
Completed
- Conditions
- Bacterial Infections
- First Posted Date
- 2002-05-07
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT00035854
- Locations
- 🇺🇸
Research Center, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath